Cargando…

Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study

BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Mitsunori, Inomata, Sho, Yamaguchi, Hikaru, Saito, Takuro, Suzuki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360220/
https://www.ncbi.nlm.nih.gov/pubmed/37475037
http://dx.doi.org/10.1186/s13019-023-02310-5
_version_ 1785076054956703744
author Higuchi, Mitsunori
Inomata, Sho
Yamaguchi, Hikaru
Saito, Takuro
Suzuki, Hiroyuki
author_facet Higuchi, Mitsunori
Inomata, Sho
Yamaguchi, Hikaru
Saito, Takuro
Suzuki, Hiroyuki
author_sort Higuchi, Mitsunori
collection PubMed
description BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. METHODS: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. RESULTS: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). CONCLUSIONS: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.
format Online
Article
Text
id pubmed-10360220
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103602202023-07-22 Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study Higuchi, Mitsunori Inomata, Sho Yamaguchi, Hikaru Saito, Takuro Suzuki, Hiroyuki J Cardiothorac Surg Research BACKGROUND: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. METHODS: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. RESULTS: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). CONCLUSIONS: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery. BioMed Central 2023-07-20 /pmc/articles/PMC10360220/ /pubmed/37475037 http://dx.doi.org/10.1186/s13019-023-02310-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Higuchi, Mitsunori
Inomata, Sho
Yamaguchi, Hikaru
Saito, Takuro
Suzuki, Hiroyuki
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title_full Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title_fullStr Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title_full_unstemmed Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title_short Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
title_sort salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360220/
https://www.ncbi.nlm.nih.gov/pubmed/37475037
http://dx.doi.org/10.1186/s13019-023-02310-5
work_keys_str_mv AT higuchimitsunori salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy
AT inomatasho salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy
AT yamaguchihikaru salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy
AT saitotakuro salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy
AT suzukihiroyuki salvagesurgeryforadvancednonsmallcelllungcancerfollowingpreviousimmunotherapyaretrospectivestudy